Cognitive decline is one of the most important consequences of aging and pharmacological therapies had been largely unsuccessful. Other strategies include the use of functional foods to reduce the burden of cognitive decline. The MFGM is an important source of polar lipids and glycoproteins that decline in the aging brain. We have developed a milk drink fortified with MFGM (MFGM-M) as a dietary supplement and studied it in a randomized clinical pilot study. Forty-four > 65-year-old healthy or mildly cognitively impaired subjects received MFGM-M or control milk (CM) for 14 weeks, during which they underwent a battery of cognitive tests. Lipidomic analyzes were also performed. The female participants showed improvement in episodic memory, the ability to recall events in our lives. It is conceivable that any intervention should be started before clinical symptoms manifest, as a preventive measure against cognitive decline. Future long-term studies may shed further light on this point.

Milk fat globule membrane-enriched milk improves episodic memory: A randomized, parallel, double-blind, placebo-controlled trial in older adults

Visioli, Francesco
Investigation
;
2023

Abstract

Cognitive decline is one of the most important consequences of aging and pharmacological therapies had been largely unsuccessful. Other strategies include the use of functional foods to reduce the burden of cognitive decline. The MFGM is an important source of polar lipids and glycoproteins that decline in the aging brain. We have developed a milk drink fortified with MFGM (MFGM-M) as a dietary supplement and studied it in a randomized clinical pilot study. Forty-four > 65-year-old healthy or mildly cognitively impaired subjects received MFGM-M or control milk (CM) for 14 weeks, during which they underwent a battery of cognitive tests. Lipidomic analyzes were also performed. The female participants showed improvement in episodic memory, the ability to recall events in our lives. It is conceivable that any intervention should be started before clinical symptoms manifest, as a preventive measure against cognitive decline. Future long-term studies may shed further light on this point.
2023
File in questo prodotto:
File Dimensione Formato  
JFF-S-23-01878.pdf

accesso aperto

Tipologia: Accepted (AAM - Author's Accepted Manuscript)
Licenza: Creative commons
Dimensione 2.09 MB
Formato Adobe PDF
2.09 MB Adobe PDF Visualizza/Apri
1-s2.0-S1756464623004498-main.pdf

accesso aperto

Tipologia: Published (Publisher's Version of Record)
Licenza: Creative commons
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3500300
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 20
  • OpenAlex 20
social impact